Tuesday, December 18, 2007

BioMS Medical stock up 49 per cent on licensing deal with Eli Lilly
The Canadian Press via Yahoo! Canada News Tue, 18 Dec 2007 3:05 PM PST
EDMONTON - Shares in BioMS Medical Corp. (TSX:MS) rose nearly 38 per cent Tuesday, a day after the company announced a licensing and development deal with Eli Lilly and Co. on its lead multiple sclerosis compound.

Blood-brain Barrier: A Misunderstood Key To Finding Life-saving Cures To Brain Disease
Science Daily Tue, 18 Dec 2007 8:13 AM PST
Scientists demystify the blood-brain barrier. They suggest several strategies to propel research for treatments of brain diseases that include multiple sclerosis, Alzheimer's disease, obesity and stroke.

The blood-brain barrier: A misunderstood key to finding life-saving cures to brain disease
EurekAlert! Tue, 18 Dec 2007 6:59 AM PST
ST. LOUIS -- An international team of scientists that includes a Saint Louis University researcher suggest several strategies to propel research for treatments of brain diseases that include multiple sclerosis, Alzheimer’s disease, obesity and stroke in the January issue of the Lancet Neurology.

Nutra Pharma Announces Successful Completion Of 6-Month Patient Crossover In AMN Clinical Trial
Medical News Today Tue, 18 Dec 2007 2:13 AM PST
Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis (MS), has today announced that its drug discovery arm, ReceptoPharm, has successfully completed its six-month patient crossover in the Phase IIb/IIIa clinical trial for the treatment of Adrenomyeloneuropathy (AMN). [click link for full article]

BioMS Signs $497M Deal With Lilly For SPMS Drug
BioWorld Online - Atlanta,GA,USA
BioMS estimates that 65 percent to 75 percent of MS patients have those genes. In a Phase II trial, MBP8298 delayed median time to disease progression for ...
See all stories on this topic

Biogen Idec-Icahn Story Likely Far From Over; History Says the ...
Xconomy - Cambridge,MA,USA
What's more, Biogen partners Elan and Genentech have, respectively, certain rights to Tysabri and Rituxan. In an intriguing analysis of the failed sale ...
See all stories on this topic

0 Comments:

Post a Comment

Links to this post:

Create a Link

<< Home